US$ 28.29
glp 1 and alzheimer's Frontiers Neuroprotective Actions of Glucagon-Like Peptide-1
Description
Ongoing check-ins and nurse access keep you on track

Have patients been harmed by unsafe drug compounding

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.

Could addiction be next?

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

Real life isn't controlled
